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Objective: This study is designed to evaluate which factors would relate to deterioration of renal function
(DRF) after delivery in pregnant women with chronic kidney disease (CKD).
Materials and methods: This study included 156 singleton pregnancies of 139 women with CKD at our
institution from 2001 to 2010. DRF was deﬁned as the shift of CKD stage into another more severe stage.
The relevant variables were compared between womenwho had DRF (n ¼ 39) and the controls (n ¼ 117).
Results: The number of transplantation or dialysis cases after delivery was 5.8%. DRF occurred in 25% of
the study patients. From a logistic regression model, the factors that inﬂuence DRF were the presence of
glomerulonephritis [odds ratio (OR) 3.56, 95% conﬁdence interval (CI) 1.18e10.81], signiﬁcant proteinuria
prior to pregnancy (3 g/d or 3þ more dipstick; OR 3.43, 95% CI 1.14e10.33), and treatment with an-
tiplatelet agents (OR 0.30, 95% CI 0.09e0.94). Receiver-operating characteristic curve analysis conﬁrmed
that the estimated glomerular ﬁltration rate (eGFR) of 75 mL/min/1.73 m2 or more before conception is
not a risk factor for DRF after delivery (negative predictive value 0.788).
Conclusion: This was the ﬁrst report to reveal a clear cutoff value regarding DRF in pregnant womanwith
CKD. There is an almost 78% risk of developing DRF after delivery in patients showing eGFR of 75 mL/
min/1.73 m2 or more before conception.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Chronic kidney disease (CKD) is a healthcare problem that was
only recently acknowledged in its full dimension and is often
clinically silent until renal dysfunction enters advanced stages. In
2002, the redeﬁnition of CKD led to development of the Kidney
Disease Outcomes Quality Initiative (K/DOQI) guidelines for the
diagnosis and staging of CKD and these disease classiﬁcations are
now used worldwide [1]. The glomerular ﬁltration rate (GFR) as
assessed using the estimated GFR (eGFR) is also evaluated and the
CKD stage is classiﬁed as follows: Stage 1 (eGFR > 90 mL/min/
1.73m2), Stage 2 (89e60mL/min/1.73m2), Stage 3 (59e30mL/min/
1.73 m2), Stage 4 (29e15 mL/min/1.73 m2), or Stage 5 (<15 mL/min/s and Gynecology, Okinawa
ty, Okinawa 905-8512, Japan.
. Makino).
bstetrics & Gynecology. Published1.73 m2 or dialysis) [1e3]. Stages 1 and 2 (normal or mild renal
impairment with persistent albuminuria) affect up to 3% of women
of childbearing age (20e39 years) [2,4]. Stages 3e5 (GFR < 60 mL/
min/1.73 m2) affect approximately one in 150 women of child-
bearing age, but because of reduced fertility and an increased rate
of early miscarriage, pregnancy in these women is less common [2].
Pregnancy inwomenwithCKD is considered to behigh risk and the
knowledge of this risk guides patient counseling and follow-up [3e9].
For example, Fink et al [5] concluded that women with renal disease
were at an increased risk of preeclampsia [odds ratio (OR) 7.2, 95%
conﬁdence interval (CI) 4.2e12.5], preterm labor (PTL; OR 7.9, 95% CI
1.9e32.6), dysfunctional labor (OR 3.6, 95% CI 1.1e11.5), and cesarean
section (OR 3.1, 95% CI 2.0e4.8). Although several studies have shown
that women with CKD have an increased risk of developing adverse
maternal and fetal outcomes, whether the long-term prognosis is
inﬂuencedbypregnancyanddeliveryhas remainedunclear [6,8,10,11].
This study is designed to evaluate which factors would relate to
deterioration of renal function (DRF) after delivery in pregnant
women with CKD according to the CKD staging.by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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Study population
We evaluated 156 singleton pregnancies of 139 women who
were recruited into this caseecontrol study between January 1,
2001, and December 31, 2010. The study was conducted at the
Maternal and Perinatal Center, Tokyo Women's Medical University
Hospital. Patients' cases were singleton pregnancies of womenwith
CKD between 22 and 41 weeks of gestation. Patients who showed
multiple pregnancy or fetal anomaly or dialysis were excluded.
All patients in this study provided verbal informed consent for
study participation. This study was conducted after obtaining
approval from the Institutional Review Board of Tokyo Women's
Medical University (No. 2011-2299).
Study assessments
The gestational agewas determined based on the last menstrual
period and standard obstetric ultrasonography. All patients were
permitted to continue the pregnancy by obstetricians and were
managed in collaboration with nephrologist.
Clinical assessment was serially undertaken as follows: prior to
the pregnancy, ﬁrst check-up during pregnancy at 8e10 weeks'
gestation, and thereafter, once in the ﬁrst trimester, once in the
second trimester, and once in the third trimester. Details such as
mean arterial pressure; use of antihypertensive, immunosuppres-
sive, and antiplatelet medication; and complications were docu-
mented at each visit.
PTL was deﬁned as the demonstrated progressive dilation of the
cervix with uterine contractions before 36 weeks of gestation [12].
Premature rupture of membranes (PROM) was deﬁned as “leakage
of a watery discharge” [13]. According to the criteria of the National
High Blood Pressure Education Program, hypertensive disorders in
pregnancy can be classiﬁed as follows: chronic hypertension,
pregnancy-induced hypertension (PIH), preeclampsia, and super-
imposed preeclampsia [14]. The diagnosis of PIH was made in
women whose blood pressure reached 140/90 mmHg or greater
after the 20th week of gestation, but in whom proteinuria was not
identiﬁed [15,16]. Signiﬁcant proteinuria prior to pregnancy was
deﬁned as 24-hour urinary protein level of 3.0 g or more (or
3þ more) using a dipstick in random urine samples.
Delivery was allowed to occur with maternal indications such as
onset of PIH or intractable hypertension, fetal indications such as
nonreassuring fetal status, and gestational age more than 37 weeks.
Cesarean sections were carried out for patients who had previously
undergone cesarean section, as well as for those with dystocia, non-
reassuring fetal status, fetalmalpresentation, ormaternal indications.
Recording of maternal characteristics
The obstetric notes of the mothers were reviewed by a
researcher (Y.M). Nearly 10 variables were assessed, including de-
mographic data, pregestational factors, and prenatal events. The
pregestational factors were age, transplantation before conception,
and maternal medical history (complications and previous obstet-
ric history). The prenatal events were eGFR and obstetric compli-
cations such as preterm delivery (<37 weeks)/PROM and PIH.
Details on the onset, duration, and clinical management of any
relevant condition were also recorded.
The CKD staging
GFR was estimated using the Modiﬁcation of Diet in Renal
Disease-4 variable equation (based on the serum creatinine level,age, sex, and race) and expressed in milliliters/minute/1.73 m2 of
body surface area [10]. Patients were categorized into four groups
according to GFR and the CKD stage was classiﬁed according to the
K/DOQI guidelines [1e3]. The DRF was deﬁned as the shift of CKD
stage into another more severe stage [17]. The mean follow-up
period and diagnosis of DRF was 3.8 years (13 years at most).Statistical analysis
The results are expressed as the mean ± standard deviation. Sta-
tistical analysiswas performedusing the Chi-square test, Fisher exact
probability test, ManneWhitney U test, KruskaleWallis test, Student
t test, and a multiple regression analysis (Artech Co., Ltd., Osaka,
Japan). Receiver-operating characteristic (ROC) curve analysis was
describedwith the KaplaneMeiermethod. All p values less than 0.05
were considered signiﬁcant. ORs, with 95% CI, were calculated to
estimate the relative risk of the various risk factors for CKD in the
cases compared with the controls. The results were compared using
both univariate and multivariate analyses, and logistic regression
models were used to assess the inﬂuence of confounding factors.Results
The CKD lesions and the CKD staging in 156 singleton preg-
nancies of 139 women with CKD are shown in Table 1. Among the
156 pregnancies, before conception there were 39 pregnancies of
womenwith CKD Stage 1, 59with CKD Stage 2, 52with CKD Stage 3,
and six with CKD Stage 4. After delivery, there were 41 pregnancies
with CKD Stage 1, 45 with CKD Stage 2, 52 with CKD Stage 3, nine
with CKD Stage 4, and nine at CKD Stage 5.
Table 2 shows the maternal characteristics before conception.
There were no differences across CKD stages from the standpoint of
primipara, proteinuria prior to pregnancy, and the treatment by an-
tiplatelet agents. eGFR before conception and after delivery is also
presented. Thirty cases hadhypertension. In CKDStage 3, the number
of hypertension cases increased signiﬁcantly versus CKD Stage 1.
Twenty-eight pregnancies suffered from PIH. In CKD Stage 4, the
number of PIH cases was statistically signiﬁcant versus CKD Stage 1.
Fifty-four pregnancies suffered from preterm delivery (<37 weeks).
In CKD Stages 3 and 4, the number of preterm delivery (<37 weeks)
cases was statistically signiﬁcant versus CKD Stage 1. The number of
transplantation or dialysis procedures performed after delivery was
nine (2 from Stage 2, 4 from Stage 3, and 3 from Stage 4). Therewas a
shift from a lower to a higher CKD stage in 39 pregnancies and there
was no statistical signiﬁcance in any of the CKD stages. In the treat-
ment, antihypertensive drugs and steroids of the CKD Stage 3 cases
were statistically signiﬁcant versus the Stage 1 cases. Immunosup-
pressive agents of the CKD Stage from 2 to 4 were statistically sig-
niﬁcant versus the CKD Stage 1. Antihypertensive drugs were as
follows: alpha-methyldopa (n ¼ 19); calcium-channel blocker
(n ¼ 5); and propranolol hydrochloride (n ¼ 2).
Table 3 presents the relationship between DRF (n ¼ 39; 10
from Stage 2, 17 from Stage 3, 9 from Stage 4, and 3 from Stage 5)
and the controls (non-DRF; n ¼ 117). By univariate analysis,
glomerulonephritis, diabetic nephropathy, signiﬁcant proteinuria
prior to pregnancy (3 g/d or 3þ more dipstick), and treatment
with antiplatelet agents were signiﬁcant in DRF. Neither perinatal
deaths nor maternal deaths were seen during the observation
period.
From a logistic regressionmodel, the factors that inﬂuenced DRF
were the presence of glomerulonephritis (OR 3.56, 95% CI
1.18e10.81), signiﬁcant proteinuria prior to pregnancy (3 g/d or
3þmore dipstick; OR 3.43, 95% CI 1.14e10.33), and treatment with
antiplatelet agents (OR 0.30, 95% CI 0.09e0.94).
Table 1
Nature of the CKD lesions and CKD staging.
CKD lesions
Pregnant
women,
N ¼ 139 (n)
Pregnancies,
N ¼ 156 (n)
Before conception After delivery
CKD
Stage 1
CKD
Stage 2
CKD
Stage 3
CKD
Stage 4
CKD
Stage 5
CKD
Stage 1
CKD
Stage 2
CKD
Stage 3
CKD S
tage 4
CKD
Stage 5
(N ¼ 39) (N ¼ 59) (N ¼ 52) (N ¼ 6) (N ¼ 0) (N ¼ 41) (N ¼ 45) (N ¼ 52) (N ¼ 9) (N ¼ 9)
Immunoglobulin A
nephropathy (n ¼ 54)
46 54 7 29 17 1 0 13 18 19 3 1 (1 D)
Chronic renal
failure a (n ¼ 16)
16 16 0 1 12 3 0 0 4 9 2 1 (1 D)
Glomerulonephritis (n ¼ 17) 16 17 3 7 6 1 0 2 4 8 0 3 (2 D, 1 T)
Nephritis (n ¼ 11) 10 11 2 5 3 1 0 2 4 3 1 1 (1 T)
Nephrotic syndrome (n ¼ 12) 11 12 9 3 0 0 0 10 1 1 0 0
Diabetic nephropathy (n ¼ 10) 9 10 1 4 5 0 0 0 0 6 (1 T) 1 3 (3 D)
Congenital malformations
and deformations (n ¼ 10)
8 10 5 3 2 0 0 2 7 1 0 0
Renal agenesis (n ¼ 3) 2 3 1 1 1 0 0 1 1 1 0 0
Polycystic kidney (n ¼ 2) 1 2 0 2 0 0 0 0 2 0 0 0
Double renal pelvis and
ureter (n ¼ 1)
1 1 1 0 0 0 0 0 1 0 0 0
Cyst of kidney (n ¼ 1) 1 1 1 0 0 0 0 0 1 0 0 0
Congenital hydronephrosis (n ¼ 1) 1 1 0 0 1 0 0 0 1 0 0 0
Medullary sponge kidney (n ¼ 1) 1 1 1 0 0 0 0 1 0 0 0 0
Noonan syndrome (n ¼ 1) 1 1 1 0 0 0 0 0 1 0 0 0
Purpura nephritis (n ¼ 7) 6 7 2 4 1 0 0 3 2 1 1 0
Membranous nephropathy (n ¼ 4) 4 4 4 0 0 0 0 4 0 0 0 0
Systemic lupus nephritis (n ¼ 4) 3 4 1 1 2 0 0 1 1 2 0 0
Renovascular hypertension (n ¼ 3) 3 3 2 0 1 0 0 2 0 1 0 0
Focal glomerulosclerosis (n ¼ 2) 2 2 1 0 1 0 0 1 0 0 1 0
Calculus of kidney and ureter (n ¼ 2) 2 2 1 1 0 0 0 0 2 0 0 0
Hydronephrosis with ureteropelvic
junction obstruction (n ¼ 2)
1 2 0 1 1 0 0 0 2 0 0 0
Familial thin basement
membrane disease (n ¼ 1)
1 1 1 0 0 0 0 1 0 0 0 0
Gouty kidney (n ¼ 1) 1 1 0 0 1 0 0 0 0 1 0 0
Data are presented as n (%).
CKD ¼ chronic kidney disease; D ¼ dialysis; T ¼ transplantation.
a The diagnosis of chronic renal failure is without deﬁnite renal pathology proved.
Table 2
Clinical characteristics of the CKD patients before conception and after delivery.
CKD Stage 1 CKD Stage 2 CKD Stage 3 CKD Stage 4 p
(n ¼ 39) (n ¼ 59) (n ¼ 52) (n ¼ 6)
Before conception
Maternal age (y) a 30.4 ± 5.1 32.9 ± 4.6 33.7 ± 4.4* 31.5 ± 4.7 <0.05*
Primipara (n) 32 43 36 5 n.s.
Transplantation before conception 0 10 * 28 *,** 3 * <0.01*
<0.01**
Maternal complications before conception
Hypertension (n) 3 10 15 * 2 <0.05*
Signiﬁcant proteinuria (3 g/d or 3þ more dipstick) 4 11 5 2 n.s.
Treatment before conception (n)
Antihypertensive drugs 3 8 13 * 2 <0.05*
Steroids 12 22 28 * 3 <0.01*
Immunosuppressive agents 1 9* 27 * 3 * <0.01*
Antiplatelet agents 8 18 14 2 n.s.
eGFR (mL/min) before conception a 109.6 ± 17.7 75.6 ± 7.7 45.1 ± 8.5 23.9 ± 3.9 <0.0001
After delivery
eGFR (mL/min) after delivery a 103.4 ± 30.7 70.7 ± 20.1 43.2 ± 17.2 17.6 ± 17.7 <0.0001
Obstetrical complications (n)
Pregnancy-induced hypertension 4 9 12 3 * <0.05*
Preterm delivery (<37 wk) 8 17 24 * 5 **,# <0.05*
<0.01#
<0.05**
The deterioration of renal function 10 17 9 3 n.s.
Data are presented as n (%) or mean ± standard deviation.
CKD ¼ chronic kidney disease; eGFR ¼ estimated glomerular ﬁltration rate; n.s. ¼ not signiﬁcant.
* (vs. stage 1) ** (vs. stage 2) # (vs. stage 1).
a KruskaleWallis test.
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CKD stage from a lower to a higher stage. The cutoff value of eGFRaffecting the shift of CKD stage from a lower to a higher stage,
determined with the ROC curve analysis, was 74.4 mL/min
Table 3
Clinical characteristics of the CKD patients between case and control.
DRF (N ¼ 39) non-DRF (N ¼ 117) p
CKD lesions
Immunoglobulin A nephropathy (n ¼ 54) 10 44 0.243
Chronic renal failure (n ¼ 16) 2 14 0.361
Glomerulonephritis (n ¼ 15) 8 9 0.037
Nephritis (n ¼ 11) 2 9 0.732
Nephrotic syndrome (n ¼ 12) 2 10 0.732
Congenital malformations and deformations (n ¼ 10) 5 5 0.068
Diabetic nephropathy (n ¼ 10) 6 4 0.020
Purpura nephritis (n ¼ 7) 2 5 >0.99
Others (n ¼ 8) 2 17 0.203
Maternal age (y) 32.0 ± 4.9 32.7 ± 4.8 0.446
Primipara (n) 33 83 0.137
Maternal complications prior to pregnancy
Hypertension (n) 9 21 0.488
Signiﬁcant proteinuria (3 g/d) or 3þ more dipstick 10 12 0.016
Obstetrical complications (n)
Pregnancy-induced hypertension 8 20 0.635
Transplantation before conception 9 32 0.678
Treatment (n)
Antihypertensive drugs 8 18 0.463
Steroids 11 54 0.061
Immunosuppressive agents 9 31 0.832
Antiplatelet agents 5 37 0.003
Mode of delivery: cesarean section (n) 22 48 0.060
Mean gestational week at delivery 35.3 ± 4.7 36.6 ± 3.7 0.075
Mean birth weight (g) 2236.1 ± 892.0 2513.1 ± 761.6 0.062
Apgar score < 7
5 min (n) 3 4 0.368
Data are presented as n (%) or mean ± standard deviation.
CKD ¼ chronic kidney disease; DRF ¼ deterioration of renal function.
Figure 1. (A) Receiver-operating characteristic (ROC) curve for the estimated glomerular ﬁltration rate (eGFR) before conception as a predictor of the shift of chronic kidney disease
(CKD) stage from a lower to a higher stage. The cutoff value (74.4), sensitivity (0.615), speciﬁcity (0.479), positive predictive value (0.282), negative predictive value (0.788), and the
area under the curve (0.720) were obtained from an analysis of the ROC curve. (B) Sensitivity and speciﬁcity curve for eGFR before conception predicting renal dysfunction in
pregnant women with CKD. Each curve crossed at 74.4 mL/min/1.73 m2 before conception.
Y. Fukasawa et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 166e170 169(sensitivity ¼ 0.615, speciﬁcity ¼ 0.479, positive predictive
value ¼ 0.282 and negative predictive value ¼ 0.788, and the area
under the curve ¼ 0.720).
Discussion
Persistent studies of CKD before or after pregnancy primarily clas-
siﬁed patients on the basis of serum creatinine values in womenwith
CKD [8]. However, the accuracy of the serum creatinine level as amarkerof renal function is limited due to its nonlinear associationwith
the GFR that varies according to age, sex, and lean body mass [18]. By
contrast, the choiceofGFRasamarkerof renal functionhas theobvious
advantage of revealing a population with normal serum creatinine
level, but with signiﬁcant renal functional impairment [19]. With this
background, we examined the impact of CKD staging, based on a new
formula for eGFR, on outcomes in pregnant womenwith CKD [1e3].
There are several reports in which CKD was redeﬁned ac-
cording to the K/DOQI guidelines in pregnant women with CKD
Y. Fukasawa et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 166e170170[2,3,10,19,20]. For example, Imbasciati et al [10] evaluated fetal
and maternal outcomes of 49 pregnancies in 49 patients with
CKD Stages 3e5 followed up for a mean period of 39 months
after delivery. The authors reported that the combined presence
of baseline GFR less than 40 mL/min/1.73 m2 (<0.67 mL/s/m2)
and proteinuria with protein levels greater than 1 g/d, but not
either factor alone, predicted faster GFR loss after delivery
compared with before conception [1.17 ± 1.23 mL/min/mo vs.
0.55 ± 0.39 mL/min/mo; difference, 0.62 mL/min/mo; 95% CI
0.27e0.96 mL/min/mo (0.020 ± 0.021 mL/s/mo vs.
0.0092 ± 0.007 mL/s/mo; difference, 0.10 mL/s/mo; 95% CI
0.005e0.016 mL/s/mo)]. Moreover, the presence of both risk
factors, but not either alone, also predicted shorter time to
starting dialysis therapy or GFR halving (N ¼ 20; hazard ratio 5.2;
95% CI 1.7e15.9) [10]. By contrast, we showed that patients
showing eGFR of 75 mL/min/1.73 m2 or more before conception
were at an almost 78% risk of developing DRF after delivery in
ROC curve analysis. Our study is the ﬁrst report to reveal the
clear cutoff value regarding DRF in pregnant woman with CKD.
In this study, we showed that glomerulonephritis, signiﬁcant
proteinuria prior to pregnancy (3 g/d or 3þ more dipstick), and
treatment with antiplatelet agents were the factors that affected
DRF in pregnant women with CKD. First, we revealed a 3.56-fold
increase in risk of DRF in pregnant woman with glomerulone-
phritis. Glomerulonephritis usually shows no adverse effect if renal
function is preserved and hypertension is absent before gestation
[7]; however, an increase in cortisol and lactogen originating from
the placenta may affect renal function and severity of nephritis and
glomerular hypertension, and hyperﬁltration could become
prominent; these changes may damage the glomeruli during
pregnancy [3]. In addition, as the blood pressure increases, relax-
ation and constriction of the import arteries occur repeatedly,
damaging the endothelial cells of the glomerular arterioles and
capillaries during pregnancy. These factors cause changes in the
edematous endothelium of the glomeruli, the penetration of
mesangial cells, and ischemia of the loop and focal segmental
glomeruli [21e23]. From these ﬁndings, glomerulonephritis may be
a risk factor for DRF in pregnant women with CKD. Second, we
revealed a 3.43-fold increase in the risk of DRF in pregnant woman
with signiﬁcant proteinuria prior to pregnancy (3 g/d or 3þmore
dipstick). Piccoli et al [19] also revealed that proteinuria and hy-
pertension were correlated with outcomes in CKD. Third, we
revealed a 0.30-fold decrease in risk of DRF in pregnant woman
treated with antiplatelet agents that has not been reported previ-
ously. Thrombotic abnormalities may be present in all stages of
CKD, and CKD is characterized as a state with a prothrombotic
tendency where platelet dysfunction plays a pivotal role. Platelet
activation is heavily implicated in the prothrombotic state observed
in CKD patients, and oral antiplatelet agents have been extensively
used in these patients [24]. According to these ﬁndings, antiplatelet
agents are useful in the treatment of pregnant women with CKD.
Some limitations should be considered when interpreting the
results of this study. First, there are several limitations such as a
small sample size leading to inadequate assessment, short duration
of therapy, and selection of a heterogeneous group of patients with
CKD. Second, data were retrospectively collected as compared with
a prospective study and more prospective studies are needed to
conﬁrm the results.
Conclusion
In conclusion, our ﬁndings demonstrate that glomerulone-
phritis, signiﬁcant proteinuria prior to pregnancy (3 g/d or
3þmore on a dipstick), and treatment with antiplatelet agents are
factors that affect DRF in pregnant womenwith CKD. Moreover, theROC curve analysis conﬁrmed that there is an almost 78% risk of
developing DRF after delivery in patients showing eGFR of 75 mL/
min/1.73 m2 or more before conception.
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